Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation
Jun Kong, Fengmei Zheng, Zhidong Wang, Yuanyuan Zhang, Yifei Cheng, Hai‐Xia Fu, Meng Lv, Huan Chen, Lan‐Ping Xu, Xiaohui Zhang, Xiao‐Jun Huang, Yu Wang
Topics & Concepts
MedicineHematopoietic stem cell transplantationMinimal residual diseaseInternal medicineMyeloid leukemiaDonor lymphocyte infusionTransplantationOncologyStem cellImmunotherapyMyeloidLeukemiaGastroenterologyImmunologyCancerGeneticsBiologyAcute Myeloid Leukemia ResearchMultiple Myeloma Research and TreatmentsChronic Myeloid Leukemia Treatments